Nigel Fleeman

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

PharmacoEconomics - open

BMC cancer

Health technology assessment (Winchester, England)

University of Liverpool

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Liverpool

United Kingdom

Researcher :: Liverpool Reviews & Implementation Group (LRiG)

Publications

Nigel Fleeman, Rachel Houten, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Janette Greenhalgh, Katherine Edwards, Michelle Maden, Devarshi Bhattacharyya, Marty Chaplin, Joanne McEntee, Shien Chow, Tom Waddell
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis. Health technology assessment (Winchester, England) 28 (49) (2024)
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Marty Chaplin, Rebecca Bresnahan, Nigel Fleeman, James Mahon, Rachel Houten, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Pinki Munot
Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Rebecca Bresnahan, Rachel Houten, Janette Greenhalgh, Sarah Jane Nevitt, James Mahon, Sophie Beale, Angela Boland, Devarshi Bhattacharyya, Yenal Dundar, Joanne McEntee, Shreyans Gandhi, Nigel Fleeman, Marty Chaplin
Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open (2023)
Rachel Houten, Nigel Fleeman, James Mahon, Marty Chaplin, Katherine Edwards, Sophie Beale, Angela Boland, Yenal Dundar, Ashley Marsden, Zafar Malik, Carlo Palmieri
Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics - open 7 (3) (2023)
Nigel Fleeman, Rachel Houten, Marty Chaplin, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Rui V Duarte, Aditya Shenoy
A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC cancer 19 (1) (2019)

Nigel Fleeman.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nigel Fleeman